Serious & Notifiable Infections

On this page

Foundations: Recognition and Notification of Life-Threatening CNS and Respiratory Infections

A 32-year-old healthcare worker presents to A&E with a three-week history of night sweats, weight loss, and productive cough. Simultaneously, a 19-year-old university student arrives by ambulance with a two-hour history of severe headache, photophobia, and altered consciousness. Both scenarios represent notifiable diseases requiring immediate public health intervention. Understanding the statutory frameworks surrounding and is fundamental to preventing secondary transmission and ensuring appropriate infection control measures are implemented without delay.

Tuberculosis (TB) - Key Definitions:

  • Active TB disease: Symptomatic infection with viable Mycobacterium tuberculosis, confirmed by culture, PCR, or strong clinical/radiological evidence

    • Pulmonary TB (70-80% of cases): involves lung parenchyma, airways, or pleura
    • Extrapulmonary TB (20-30%): lymph nodes (35%), bone/joint (11%), CNS (5-10%), disseminated/miliary (3%)
  • Latent TB infection (LTBI): Asymptomatic state with positive IGRA/TST but no active disease

    • 5-10% lifetime reactivation risk (50% within first two years)
    • Not notifiable and not infectious
  • UK epidemiology (2022 data):

    • Incidence: 4,380 cases (6.7 per 100,000 population)
    • 72% in non-UK born individuals
    • London accounts for 38% of UK cases (incidence 16.1/100,000)
    • Drug-resistant TB: 1.6% multidrug-resistant (MDR), 0.3% extensively drug-resistant (XDR)

Meningitis - Key Definitions:

  • Bacterial meningitis: Inflammation of meninges caused by bacterial pathogens

    • Neisseria meningitidis (40-50% in UK): serogroups B (60%), W (20%), Y (15%)
    • Streptococcus pneumoniae (30-35%): post-vaccination era shift
    • Listeria monocytogenes (5%): neonates, elderly, immunocompromised
  • UK epidemiology:

    • Incidence: 2-5 per 100,000 population annually
    • Case fatality rate: 10% (meningococcal), 20-30% (pneumococcal)
    • Peak age groups: <5 years and 15-24 years (meningococcal); >65 years (pneumococcal)

Statutory Notification Requirements:

DiseaseNotification TriggerTimeframeResponsible Clinician
Active TB (all forms)Clinical suspicion (before confirmation)Within 3 working daysAny registered medical practitioner
Meningitis (bacterial)Clinical suspicionImmediate (same day)Any registered medical practitioner
Meningococcal septicaemiaClinical suspicionImmediate (same day)Any registered medical practitioner
  • Notification to: UK Health Security Agency (UKHSA) via local health protection team
  • Legal requirement under Health Protection (Notification) Regulations 2010
  • Failure to notify is a criminal offence (fine up to £1,000)

📌 Mnemonic for Notifiable Diseases: "TB Means Call Health Protection" - Tuberculosis, Meningitis, Cholera, Hepatitis, Plague (covers major notifiable infections)

Figure 1: Chest X-ray PA view showing bilateral upper lobe cavitation with air-fluid levels characteristic of active pulmonary tuberculosis

Figure 2: CT head showing diffuse leptomeningeal enhancement and hydrocephalus in bacterial meningitis

Foundations: Recognition and Notification of Life-Threatening CNS and Respiratory Infections

2 - Pathophysiological Mechanisms: From Transmission to Tissue Destruction

The journey from exposure to clinical disease in and involves complex host-pathogen interactions that determine infection outcomes. Understanding these mechanisms explains why certain populations develop severe disease while others remain asymptomatic, and why treatment strategies target specific stages of the infectious process.

TB Transmission and Infection Dynamics:

  • Airborne transmission: Droplet nuclei (1-5 μm) containing 1-3 bacilli remain suspended for hours

    • Single cough: 3,000 droplet nuclei expelled
    • Infectivity correlates with bacillary load (smear-positive patients most infectious)
    • 30% close contact infection rate for untreated smear-positive pulmonary TB
  • Primary infection sequence:

    • Alveolar macrophage phagocytosis → initial bacterial replication (bacilli double every 15-20 hours)
    • T-cell mediated immunity develops at 2-8 weeks
    • Granuloma formation: central caseous necrosis surrounded by epithelioid macrophages, Langhans giant cells, lymphocytes
    • 90% control infection → LTBI; 10% progress to active disease (5% within 2 years, 5% later reactivation)
  • Reactivation risk factors (quantified):

    • HIV co-infection: 10% annual reactivation risk (100-fold increase)
    • TNF-α inhibitor therapy: 4-fold increased risk
    • Diabetes mellitus: 3-fold increased risk
    • End-stage renal disease: 10-25-fold increased risk

Meningitis Pathogenesis:

  • Bacterial invasion routes:

    • Haematogenous spread (90%): nasopharyngeal colonisation → bloodstream → blood-brain barrier (BBB) penetration
    • Direct extension: sinusitis, mastoiditis, skull fracture
    • CSF shunt infection: Staphylococcus species predominate
  • BBB disruption cascade:

    • Bacterial adherence to choroid plexus and cerebral endothelium
    • Cytokine release (TNF-α, IL-1β, IL-6) increases BBB permeability
    • Neutrophil influx and bacterial lysis release inflammatory mediators
    • Vasogenic and cytotoxic cerebral oedema develops within 24-48 hours
  • Complications mechanisms:

    • Raised intracranial pressure (ICP): cerebral oedema + hydrocephalus (CSF outflow obstruction)
    • Vasculitis → cerebral infarction (20-30% of cases)
    • SIADH (30%): hypothalamic involvement
    • Seizures (20-30%): cortical irritation and metabolic derangement

2 — Pathophysiological Mechanisms: From Transmission to Tissue Destruction

3 - Clinical Assessment: Diagnostic Pathways for Serious Infections

A 45-year-old man from Bangladesh presents with six weeks of productive cough, haemoptysis, and 8 kg weight loss. Chest X-ray shows right upper lobe consolidation with cavitation. Meanwhile, a 21-year-old student develops fever, severe headache, and neck stiffness over four hours, with a non-blanching purpuric rash on her legs. These presentations demand immediate, systematic diagnostic approaches following evidence-based algorithms as outlined in and .

TB Diagnostic Pathway (NICE NG33):

  • Clinical assessment priorities:

    • Persistent cough >3 weeks (sensitivity 50-70% for active TB)
    • Constitutional symptoms: fever, night sweats, weight loss (>5% body weight)
    • Haemoptysis (present in 20% pulmonary TB)
    • Risk factors: HIV, immunosuppression, endemic country origin, homeless, substance misuse
  • Investigations sequence:

    • Chest X-ray: First-line imaging (sensitivity 70-80%, specificity 85-95%)
      • Upper lobe predominance (85% of reactivation TB)
      • Cavitation indicates high bacillary load and infectivity
    • Sputum microscopy and culture: 3 early morning samples
      • Ziehl-Neelsen stain: sensitivity 50-60% (requires 5,000-10,000 bacilli/mL)
      • Culture (Löwenstein-Jensen media): gold standard, 6-8 weeks, sensitivity 80-85%
    • Nucleic acid amplification tests (NAATs): GeneXpert MTB/RIF
      • Sensitivity 98% (smear-positive), 67% (smear-negative)
      • Detects rifampicin resistance (proxy for MDR-TB) in 2 hours
    • Interferon-gamma release assays (IGRAs): QuantiFERON-TB Gold, T-SPOT.TB
      • Sensitivity 80-90% for LTBI; does not distinguish active from latent TB
      • False negatives in immunosuppression (15-20%)

Meningitis Diagnostic Pathway (NICE NG240):

  • Clinical assessment (immediate):

    • Meningism triad: headache, photophobia, neck stiffness (sensitivity 95% when all present)
    • Altered consciousness (GCS <14): present in 70% bacterial meningitis
    • Fever >38°C (sensitivity 85%)
    • Non-blanching rash (30% meningococcal disease, highly specific)
  • Investigations sequence:

    • Blood cultures: Before antibiotics (positive in 50-70%)
    • Lumbar puncture: Unless contraindicated (see below)
    • CT head before LP if:
      • GCS ≤12 or focal neurological signs
      • New-onset seizures
      • Papilloedema or signs of raised ICP
      • Immunocompromised state
CSF ParameterBacterialViralTB
Opening pressure>25 cmH₂ONormal>25 cmH₂O
WCC (cells/μL)100-10,000 (neutrophils >80%)10-1,000 (lymphocytes >50%)10-500 (lymphocytes >50%)
Protein (g/L)>1.00.4-0.81.0-5.0
Glucose (CSF:serum ratio)<0.4>0.6<0.5
Gram stain sensitivity60-90%N/A<20% (Ziehl-Neelsen)

🚩 Red Flag: Do NOT delay antibiotics for LP. If meningococcal disease suspected, give IV benzylpenicillin 1.2 g (or ceftriaxone 2 g) immediately, even in community settings.

Figure 3: Lumbar puncture showing turbid CSF with elevated opening pressure in bacterial meningitis

Figure 4: Ziehl-Neelsen stain showing acid-fast bacilli appearing as red rods against blue background

3 — Clinical Assessment: Diagnostic Pathways for Serious Infections

4 - Differential Diagnosis: Distinguishing Life-Threatening Mimics

Differentiating from other chronic respiratory infections and from alternative causes of acute encephalopathy requires systematic analysis of discriminating features. Cognitive errors-particularly anchoring bias (fixating on initial diagnosis) and premature closure (stopping diagnostic workup too early)-account for 30-40% of missed diagnoses in serious infections.

TB Differential Analysis:

FeaturePulmonary TBBacterial PneumoniaLung CancerFungal Infection
OnsetSubacute (weeks-months)Acute (days)Insidious (months)Subacute (weeks)
Fever patternLow-grade, night sweatsHigh-grade, rigorsLow-grade or absentIntermittent
HaemoptysisStreaky (20%)Rusty sputum (30%)Frank blood (40%)Rare
CXR distributionUpper lobe, cavitationLobar consolidationMass ± lymphadenopathyNodules, halo sign
Sputum smearAFB positiveGram stain organismsCytology: malignant cellsKOH prep: hyphae
Response to antibioticsNone (standard)Rapid (48-72h)NoneNone (standard)

Key discriminators for TB:

  • Cavitation on CXR: 80% specificity for TB vs. other infections
  • Weight loss >10%: Present in 60% TB, <10% community-acquired pneumonia
  • Duration >3 weeks: 90% sensitivity for excluding acute bacterial infection
  • Endemic exposure: Relative risk 5-10× for TB

Meningitis Differential Analysis:

CSF FeatureBacterialViralTBFungal (Cryptococcal)
OnsetHoursDaysWeeksWeeks
Glucose<2.2 mmol/LNormal<2.2 mmol/L<2.2 mmol/L
Protein>1.0 g/L<0.8 g/L1.0-5.0 g/L>1.0 g/L
Neutrophils>80%<50%<50% (early may be neutrophilic)<20%
Specific testsGram stain, PCRViral PCRAFB, TB PCRIndia ink, antigen
Lactate>4 mmol/L<2 mmol/L>4 mmol/LVariable

Common diagnostic pitfalls:

  • Partially treated bacterial meningitis: Prior antibiotics cause lymphocytic predominance (mimics viral/TB)
    • CSF lactate >3.5 mmol/L retains 96% sensitivity for bacterial aetiology
  • Early TB meningitis: Neutrophil predominance in first 7-10 days
    • Serial LPs show lymphocyte shift over 48-72 hours
  • Immunocompromised patients: Blunted CSF inflammatory response
    • Cryptococcal antigen testing mandatory in HIV patients (sensitivity >95%)

Clinical Pearl: CSF lactate >3.5 mmol/L distinguishes bacterial from viral meningitis with 93% sensitivity and 96% specificity-more reliable than glucose or protein alone in partially treated cases.

4 — Differential Diagnosis: Distinguishing Life-Threatening Mimics

5 - Evidence-Based Management: Precision Treatment Strategies

The management of and exemplifies the principle of "time-to-treatment determines outcome." For bacterial meningitis, every hour delay in antibiotic administration increases mortality by 8%. For TB, early treatment prevents transmission (patients become non-infectious within 2 weeks of appropriate therapy) and reduces mortality from 50% (untreated) to <5% (treated). NICE guidelines emphasize immediate empirical therapy while awaiting microbiological confirmation.

TB Treatment (NICE NG33):

  • Standard regimen (drug-sensitive TB):

    • Intensive phase (2 months): Rifampicin 600 mg, Isoniazid 300 mg, Pyrazinamide 2 g, Ethambutol 1200 mg (all once daily)
    • Continuation phase (4 months): Rifampicin 600 mg + Isoniazid 300 mg
    • Total duration: 6 months (pulmonary); 12 months (CNS/bone)
  • Monitoring requirements:

    • Baseline: LFTs, U&Es, FBC, visual acuity (ethambutol)
    • During treatment: LFTs at 2, 4, 8 weeks (10-20% develop transaminitis)
    • Treatment response: Sputum culture at 2, 4, 6 months (should convert by 2 months)
    • Drug levels: If malabsorption suspected or treatment failure
  • MDR-TB treatment (resistance to rifampicin + isoniazid):

    • Minimum 5 drugs for 18-24 months
    • Regimen design: bedaquiline, linezolid, fluoroquinolone (levofloxacin 750 mg), cycloserine, clofazimine
    • Specialist centre management mandatory

Meningitis Treatment (NICE NG240):

  • Empirical therapy (immediate):

    • Age 3 months-60 years: Ceftriaxone 2 g IV 12-hourly
    • Age >60 years or immunocompromised: Ceftriaxone 2 g IV 12-hourly + Amoxicillin 2 g IV 4-hourly (for Listeria)
    • Penicillin allergy: Chloramphenicol 25 mg/kg IV 6-hourly
  • Adjunctive dexamethasone:

    • Dose: 10 mg IV 6-hourly for 4 days
    • Timing: Before or with first antibiotic dose (NNT = 10 to prevent death/disability)
    • Evidence: Reduces mortality in pneumococcal meningitis (RR 0.7, 95% CI 0.5-0.9)
    • Contraindications: Septic shock, immunosuppression, TB meningitis (increases mortality)
OrganismTargeted AntibioticDurationAdditional Therapy
N. meningitidisCeftriaxone 2 g IV 12-hourly7 daysDexamethasone 4 days
S. pneumoniaeCeftriaxone 2 g IV 12-hourly14 daysDexamethasone 4 days
ListeriaAmoxicillin 2 g IV 4-hourly + Gentamicin 7 mg/kg IV daily21 daysNo steroids
M. tuberculosisRHZE (as above)12 monthsNo dexamethasone

🚩 Red Flag: Never delay antibiotics for imaging or LP. Mortality increases 8% per hour without treatment. Administer ceftriaxone within 60 minutes of hospital arrival.

5 — Evidence-Based Management: Precision Treatment Strategies

6 - Complex Scenarios: Managing High-Risk Populations and Complications

Real-world management of and frequently involves patients with multimorbidity, immunosuppression, or drug resistance. These scenarios demand synthesis of multiple guidelines, specialist input, and individualised risk-benefit analysis. Recent evidence emphasises the importance of multidisciplinary team (MDT) involvement for optimal outcomes.

TB in Special Populations:

  • HIV co-infection (CD4 <200 cells/μL):

    • Paradoxical TB-IRIS (immune reconstitution inflammatory syndrome): occurs in 10-40% when ART initiated
    • Timing of ART: Start within 2 weeks if CD4 <50; within 8 weeks if CD4 50-200
    • Drug interactions: Rifampicin induces CYP3A4 (reduces efavirenz, dolutegravir levels)
    • Solution: Increase dolutegravir to 50 mg twice daily or use rifabutin
  • Pregnancy:

    • Standard RHZE regimen safe (avoid streptomycin-ototoxicity)
    • Pyridoxine 25 mg daily mandatory (prevents isoniazid-induced neuropathy)
    • Breastfeeding safe with all first-line agents
  • Chronic kidney disease (eGFR <30 mL/min):

    • Adjust dosing: Ethambutol and pyrazinamide require 50% dose reduction
    • Monitor drug levels (therapeutic drug monitoring essential)

MDR-TB Management:

  • Regimen construction principles:

    • Minimum 5 effective drugs (4 likely effective + 1 uncertain)
    • Group A drugs (include all unless contraindicated): levofloxacin, moxifloxacin, bedaquiline, linezolid
    • Treatment duration: 18-20 months total (15-17 months after culture conversion)
  • Adverse effect monitoring:

    • Linezolid: Weekly FBC (myelosuppression in 60%), peripheral neuropathy (20%)
    • Bedaquiline: ECG monthly (QTc prolongation-discontinue if >500 ms)
    • Fluoroquinolones: Tendon rupture risk (1-2%), psychiatric effects

Meningitis Complications:

  • Raised ICP management:

    • Head elevation 30°, normocapnia (PaCO₂ 4.5-5.0 kPa)
    • Hypertonic saline 3% (2-5 mL/kg bolus) if signs of herniation
    • Avoid routine hyperventilation (causes cerebral ischaemia)
    • Neurosurgery referral if hydrocephalus (external ventricular drain)
  • Seizure management:

    • Occurs in 20-30% bacterial meningitis
    • First-line: Levetiracetam 1000 mg IV (no drug interactions)
    • Avoid phenytoin if possible (interacts with ceftriaxone)
ComplicationIncidenceManagementOutcome Impact
Cerebral oedema60-80%Hypertonic saline, head elevationMortality 30% if severe
Seizures20-30%Levetiracetam 1000 mg IVDoubles mortality risk
Hearing loss10-30%Dexamethasone (preventive)Permanent in 50%
Hydrocephalus15-25%EVD if symptomaticRequires long-term shunt in 30%

Clinical Pearl: In MDR-TB, therapeutic drug monitoring (TDM) improves culture conversion rates by 20-30%. Target peak levels: levofloxacin 8-12 mg/L, linezolid 2-7 mg/L.

6 — Complex Scenarios: Managing High-Risk Populations and Complications

High Yield Summary

Key Take-Aways:

  • Active TB and bacterial meningitis are statutory notifiable diseases requiring immediate reporting to UKHSA (meningitis same-day, TB within 3 days)
  • TB diagnosis requires 3 sputum samples for microscopy, culture, and GeneXpert MTB/RIF (98% sensitivity for smear-positive disease, detects rifampicin resistance in 2 hours)
  • Bacterial meningitis management: dexamethasone 10 mg IV before/with first antibiotic dose (NNT=10 for death/disability prevention in pneumococcal disease)
  • CSF lactate >3.5 mmol/L distinguishes bacterial from viral meningitis with 93% sensitivity, 96% specificity-more reliable than glucose in partially treated cases
  • Standard TB treatment: 2 months RHZE (rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 2 g, ethambutol 1200 mg) then 4 months RH; extend to 12 months for CNS/bone TB
  • Every hour delay in meningitis antibiotic administration increases mortality by 8%-never delay for imaging or LP
  • MDR-TB requires minimum 5 drugs for 18-24 months with specialist centre management and therapeutic drug monitoring

Essential Numbers/Formulas:

ParameterCritical ValueClinical Significance
TB sputum conversion2 months90% should be culture-negative; failure indicates resistance
CSF glucose (bacterial)<2.2 mmol/L or ratio <0.4Sensitivity 80%, specificity 98%
CSF WCC (bacterial)>100 cells/μL (>80% neutrophils)Distinguishes from viral (lymphocytic)
Meningitis antibiotic window<60 minutes from arrivalEach hour delay = 8% mortality increase
TB cavitation infectivity10⁵-10⁷ bacilli/mL sputumHighly infectious until 2 weeks treatment
Dexamethasone NNT10Prevents 1 death/severe disability in pneumococcal meningitis

Key Principles/Pearls:

  • TB contact tracing: Screen all close contacts (>8 hours cumulative exposure) with IGRA and chest X-ray; treat LTBI in HIV+, age <35, or healthcare workers
  • Meningitis LP contraindications: GCS ≤12, focal neurology, new seizures, papilloedema, immunosuppression-CT first, but never delay antibiotics
  • Partially treated meningitis: CSF may show lymphocytic predominance mimicking viral/TB; CSF lactate remains elevated (>3.5 mmol/L) with 96% specificity for bacterial aetiology
  • Rifampicin drug interactions: Potent CYP3A4 inducer-reduces efficacy of oral contraceptives, warfarin, antiretrovirals; requires dose adjustments or alternative agents
  • Common mistake: Stopping TB treatment at 6 months for CNS/bone disease (requires 12 months minimum)

Quick Reference:

Clinical ScenarioImmediate ActionKey InvestigationDefinitive Treatment
Suspected meningococcal diseaseBenzylpenicillin 1.2 g IV or ceftriaxone 2 g IVBlood cultures, LP if no contraindicationsCeftriaxone 2 g IV 12-hourly × 7 days
Cavitary pulmonary TBRespiratory isolation3× sputum for AFB, culture, GeneXpertRHZE × 2 months → RH × 4 months
TB in HIV (CD4 <50)Start TB treatment immediatelyBaseline CD4, viral load, drug resistanceStandard RHZE + ART within 2 weeks
MDR-TB confirmedSpecialist TB centre referralDrug susceptibility testing, TDM≥5 drugs (bedaquiline, linezolid, fluoroquinolone) × 18-24 months

</budget:token_budget>

Practice Questions: Serious & Notifiable Infections

Test your understanding with these related questions

A 58-year-old woman with diabetes presents with severe foot pain and a deep ulcer exposing bone. X-ray shows osteolytic changes. What is the most likely complication?

1 of 5

Flashcards: Serious & Notifiable Infections

1/10

The mnemonic FROM JANE describes the symptoms of _____

TAP TO REVEAL ANSWER

The mnemonic FROM JANE describes the symptoms of _____

infective (bacterial) endocarditis

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial